Mark Bazett

Mark Bazett has over 10 years of experience in the biotechnology field. Mark is currently serving as the Senior Director of Preclinical Development at Bold Therapeutics Inc., where they lead the preclinical research team and manages various scientific initiatives. Mark has also successfully built a global network of academic experts and led the development of the BOLD-100 COVID-19 program. Prior to this, they worked as the Preclinical Immunotherapy Lead at Novelogics Biotechnology Inc., overseeing the preclinical drug development of a novel antibody treatment for cancer. Mark also has experience at Qu Biologics Inc., where they directed the preclinical and translational research efforts and contributed to various scientific publications. Mark began their career as a PhD candidate at McGill University, studying the interaction between gut bacteria, immune system, and lung mechanics in cystic fibrosis. Mark has a strong background in preclinical research, project management, and academic collaborations.

Mark Bazett earned their Bachelor of Science degree in Biochemistry from the University of Victoria in 2009. After that, they pursued a Doctor of Philosophy in Human Genetics from McGill University and completed their degree in 2015.